Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for VNDA

Stock NameVanda Pharmaceuticals Inc
TickerVNDA(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS9216591084
LEI529900AY8VOOQBKJ0O70

Show aggregate VNDA holdings

News associated with VNDA

XTX Topco Ltd Has $318,000 Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
XTX Topco Ltd grew its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 378.3% during the first quarter, HoldingsChannel.com reports. The firm owned 69,329 shares of the biopharmaceutical company’s stock after acquiring an additional 54,833 shares during the quarter. XTX Topco Ltd’s holdings in Vanda Pharmaceuticals were worth $318,000 as of […] - 2025-08-11 05:34:58
Vanda (VNDA) Q2 Revenue Rises 4%
Key PointsNet loss (GAAP) widened sharply due to increased spending in Q2 2025, with GAAP EPS was ($0.46) for Q2 2025. - 2025-08-01 05:18:57
GSA Capital Partners LLP Raises Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
GSA Capital Partners LLP increased its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 88.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 260,215 shares of the biopharmaceutical company’s stock after acquiring an additional 121,797 shares during the […] - 2025-07-31 04:29:06
Public Employees Retirement System of Ohio Has $426,000 Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Public Employees Retirement System of Ohio reduced its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 16.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 89,032 shares of the biopharmaceutical company’s stock after selling 17,200 shares during the period. Public Employees Retirement System of Ohio […] - 2025-06-05 05:23:00
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Acquired by Two Sigma Advisers LP
Two Sigma Advisers LP raised its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 11.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 156,300 shares of the biopharmaceutical company’s stock after acquiring an additional 15,700 shares […] - 2025-06-03 04:56:54
Short Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Expands By 21.4%
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Get Free Report) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 4,880,000 shares, an increase of 21.4% from the March 31st total of 4,020,000 shares. Based on an average daily volume of 663,100 shares, the days-to-cover ratio is currently 7.4 […] - 2025-05-05 02:35:06
XTX Topco Ltd Makes New Investment in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
XTX Topco Ltd purchased a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 14,496 shares of the biopharmaceutical company’s stock, valued at approximately $69,000. A number of other hedge funds also recently modified their holdings of VNDA. Geode Capital Management LLC boosted […] - 2025-05-01 05:28:58
Geode Capital Management LLC Buys 24,483 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Geode Capital Management LLC raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The fund owned 1,450,310 shares of the biopharmaceutical company’s stock after acquiring an additional 24,483 shares during the period. Geode Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $6,949,000 […] - 2025-04-25 04:26:50
Vanguard Group Inc. Has $16.80 Million Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Vanguard Group Inc. lessened its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 3.4% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,506,287 shares of the biopharmaceutical company’s stock after selling 125,002 shares during the period. Vanguard Group Inc. owned approximately 0.06% of Vanda Pharmaceuticals worth $16,795,000 as of its most […] - 2025-04-17 04:25:09
ExodusPoint Capital Management LP Decreases Stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
ExodusPoint Capital Management LP trimmed its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 74.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 31,506 shares of the biopharmaceutical company’s stock after selling 94,144 shares during the quarter. ExodusPoint […] - 2025-04-15 04:39:18
American Century Companies Inc. Raises Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
American Century Companies Inc. increased its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 2.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 300,276 shares of the biopharmaceutical company’s stock after acquiring an additional 6,079 shares during the […] - 2025-04-10 04:28:52
135,400 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Bought by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS bought a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 135,400 shares of the biopharmaceutical company’s stock, valued at approximately $649,000. KLP Kapitalforvaltning AS owned […] - 2025-04-02 05:16:59
Bank of New York Mellon Corp Cuts Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)
Bank of New York Mellon Corp lessened its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA – Free Report) by 14.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 175,017 shares of the biopharmaceutical company’s stock after selling 30,260 shares during the quarter. Bank of New York Mellon Corp’s […] - 2025-03-26 05:12:48
Reviewing Vanda Pharmaceuticals (NASDAQ:VNDA) & Rapport Therapeutics (NASDAQ:RAPP)
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-03-25 03:36:46
Vanda Pharmaceuticals (NASDAQ:VNDA) Given New $20.00 Price Target at HC Wainwright
Vanda Pharmaceuticals (NASDAQ:VNDA – Free Report) had its price target upped by HC Wainwright from $18.00 to $20.00 in a research note issued to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, February 5th. […] - 2025-02-19 04:56:52
Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by StockNews.com
Analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research report […] - 2025-02-07 04:20:53
Comparing Vanda Pharmaceuticals (NASDAQ:VNDA) & Cyclerion Therapeutics (NASDAQ:CYCN)
Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Profitability This table compares Vanda Pharmaceuticals and […] - 2025-02-05 04:26:43

iShares Healthcare Innovation UCITS ETF USD (Acc) VNDA holdings

DateNumber of VNDA Shares HeldBase Market Value of VNDA SharesLocal Market Value of VNDA SharesChange in VNDA Shares HeldChange in VNDA Base ValueCurrent Price per VNDA Share HeldPrevious Price per VNDA Share Held
2025-11-27 (Thursday)68,470USD 362,891USD 362,8910USD 0 USD 5.3 USD 5.3
2025-11-26 (Wednesday)68,470USD 362,891VNDA holding increased by 20541USD 362,8910USD 20,541 USD 5.3 USD 5
2025-11-25 (Tuesday)68,470USD 342,350VNDA holding increased by 7532USD 342,3500USD 7,532 USD 5 USD 4.89
2025-11-24 (Monday)68,470USD 334,818VNDA holding increased by 6162USD 334,8180USD 6,162 USD 4.89 USD 4.8
2025-11-21 (Friday)68,470USD 328,656VNDA holding decreased by -2739USD 328,6560USD -2,739 USD 4.8 USD 4.84
2025-11-20 (Thursday)68,470USD 331,395VNDA holding decreased by -20541USD 331,3950USD -20,541 USD 4.84 USD 5.14
2025-11-19 (Wednesday)68,470USD 351,936VNDA holding decreased by -14379USD 351,9360USD -14,379 USD 5.14 USD 5.35001
2025-11-18 (Tuesday)68,470USD 366,315VNDA holding increased by 65047USD 366,3150USD 65,047 USD 5.35001 USD 4.4
2025-11-17 (Monday)68,470USD 301,268VNDA holding increased by 3423USD 301,2680USD 3,423 USD 4.4 USD 4.35001
2025-11-14 (Friday)68,470VNDA holding decreased by -644USD 297,845VNDA holding decreased by -2110USD 297,845-644USD -2,110 USD 4.35001 USD 4.34
2025-11-13 (Thursday)69,114USD 299,955VNDA holding decreased by -4838USD 299,9550USD -4,838 USD 4.34 USD 4.41
2025-11-12 (Wednesday)69,114USD 304,793VNDA holding increased by 2074USD 304,7930USD 2,074 USD 4.41 USD 4.38
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of VNDA by Blackrock for IE00BYZK4776

Show aggregate share trades of VNDA

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-14SELL-644 4.350* 4.67 Profit of 3,008 on sale
2025-10-24SELL-6025.5005.620 5.608USD -3,376 4.67 Loss of -565 on sale
2025-09-11BUY3094.6004.600 4.600USD 1,421 4.62
2025-07-08SELL-3004.8604.980 4.968USD -1,490 4.61 Loss of -108 on sale
2025-06-24SELL-3154.5004.510 4.509USD -1,420 4.60 Profit of 27 on sale
2025-06-23SELL-3154.4704.550 4.542USD -1,431 4.60 Profit of 17 on sale
2025-06-11SELL-3084.5804.720 4.706USD -1,449 4.60 Loss of -33 on sale
2025-05-30SELL-3094.3404.410 4.403USD -1,361 4.61 Profit of 63 on sale
2025-05-21BUY3094.3204.470 4.455USD 1,377 4.63
2025-05-14SELL-1,8363.9203.980 3.974USD -7,296 4.64 Profit of 1,228 on sale
2025-04-30SELL-3044.5104.540 4.537USD -1,379 4.68 Profit of 42 on sale
2025-04-28SELL-3044.3004.320 4.318USD -1,313 4.68 Profit of 111 on sale
2025-04-25SELL-3044.2504.280 4.277USD -1,300 4.69 Profit of 125 on sale
2025-04-11SELL-1,9324.1304.160 4.157USD -8,031 4.72 Profit of 1,086 on sale
2025-04-08SELL-9394.1404.300 4.284USD -4,023 4.74 Profit of 428 on sale
2025-04-07SELL-6484.1904.260 4.253USD -2,756 4.75 Profit of 320 on sale
2025-03-31SELL-6244.5904.730 4.716USD -2,943 4.76 Profit of 28 on sale
2025-03-21SELL-6124.7704.960 4.941USD -3,024 4.76 Loss of -109 on sale
2025-03-12SELL-3224.9505.100 5.085USD -1,637 4.74 Loss of -110 on sale
2025-02-28SELL-3234.7604.790 4.787USD -1,546 4.73 Loss of -19 on sale
2025-02-25BUY3244.4604.500 4.496USD 1,457 4.73
2025-02-20SELL-3244.4904.650 4.634USD -1,501 4.75 Profit of 37 on sale
2025-02-19BUY6484.5504.640 4.631USD 3,001 4.75
2025-02-18BUY3244.4604.600 4.586USD 1,486 4.76
2024-12-30SELL-6184.7804.900 4.888USD -3,021 4.88 Loss of -7 on sale
2024-12-06SELL-2964.8404.870 4.867USD -1,441 4.89 Profit of 6 on sale
2024-12-04SELL-2974.8404.910 4.903USD -1,456 4.89 Loss of -3 on sale
2024-12-03SELL-5984.9105.040 5.027USD -3,006 4.89 Loss of -80 on sale
2024-11-21SELL-3174.9404.940 4.940USD -1,566 4.82 Loss of -39 on sale
2024-11-20SELL-3244.9004.920 4.918USD -1,593 4.81 Loss of -35 on sale
2024-11-19SELL-3254.9204.960 4.956USD -1,611 4.80 Loss of -49 on sale
2024-11-18SELL-1,2244.9805.070 5.061USD -6,195 4.79 Loss of -327 on sale
2024-11-12SELL-3055.4005.550 5.535USD -1,688 4.75 Loss of -238 on sale
2024-11-07SELL-3045.0205.300 5.272USD -1,603 4.70 Loss of -174 on sale
2024-11-05SELL-6104.7904.800 4.799USD -2,927 4.67 Loss of -76 on sale
2024-10-28SELL-3074.7804.790 4.789USD -1,470 4.64 Loss of -45 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of VNDA

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1942,7742,453131,24432.6%
2025-09-1825,4870103,69724.6%
2025-09-1742,313099,51342.5%
2025-09-1616,5920110,45315.0%
2025-09-1549,9984,027122,73340.7%
2025-09-1255,8420160,48834.8%
2025-09-1142,4470110,25638.5%
2025-09-1025,1131,000115,79021.7%
2025-09-0931,12944670,77344.0%
2025-09-0828,194068,40041.2%
2025-09-0527,0680125,69721.5%
2025-09-04113,95617,115231,50749.2%
2025-09-0354,3400112,43648.3%
2025-09-0252,5924,793241,17421.8%
2025-08-2926,190081,42132.2%
2025-08-2845,8980150,18930.6%
2025-08-2719,3685,60096,93520.0%
2025-08-2652,199200124,70441.9%
2025-08-2540,000199161,31024.8%
2025-08-2245,0030127,80135.2%
2025-08-2157,6780170,95233.7%
2025-08-2022,3470105,69221.1%
2025-08-1955,399203176,14831.5%
2025-08-18188,37411,471480,63139.2%
2025-08-1547,3580111,57542.4%
2025-08-1456,8457138,85040.9%
2025-08-1347,9900178,44326.9%
2025-08-1283,1808,700251,64233.1%
2025-08-1158,8030148,16339.7%
2025-08-0857,3090117,85948.6%
2025-08-0787,9192,763143,06661.5%
2025-08-06139,4423,417252,62355.2%
2025-08-0571,9280173,00741.6%
2025-08-04102,812118269,24738.2%
2025-08-01168,3319,932356,47047.2%
2025-07-31366,63025,169758,40448.3%
2025-07-30101,62219,723407,51424.9%
2025-07-2954,8330160,27334.2%
2025-07-2835,6698,395106,25633.6%
2025-07-2590,5194154,63758.5%
2025-07-2449,307648146,92733.6%
2025-07-2369,3190165,08942.0%
2025-07-2242,7688,190106,05840.3%
2025-07-2151,559500211,90924.3%
2025-07-1852,51010131,90439.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.